Netherlands' Philips Q1 sales rise 4% yr/yr

Koninklijke Philips

06/05/2026 06:13

Overview

Dutch health technology firm's Q1 comparable sales rose 4% yr/yr to EUR 3.9 bln

Q1 income from operations increased to EUR 241 mln

Company to repurchase up to 4 mln shares, valued at about EUR 91 mln

Outlook

Philips reiterates 2026 comparable sales growth outlook of 3%-4.5%

Company expects 2026 adjusted EBITA margin of 12.5%-13.0%

Philips sees 2026 free cash flow of EUR 1.3-1.5 bln

Result Drivers

ORDER INTAKE & SEGMENT GROWTH - Co said 6% growth in comparable order intake and sales increases across all segments, led by Personal Health, drove results

PRODUCTIVITY & COST ACTIONS - Productivity initiatives and cost management delivered EUR 126 mln in savings, helping offset higher tariffs and cost inflation

Company press release: ID:nGNE3FLNQ2

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
EUR 3.90 bln
Q1 Adjusted Free Cash Flow
EUR 188 mln
Q1 Free Cash Flow
EUR 28 mln
Q1 Operating Income
EUR 241 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 12 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Koninklijke Philips NV is €27.25, about 20.3% above its May 5 closing price of €22.65

The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 16 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)